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Abstract
Background: While high-quality meta-analyses have confirmed the effectiveness of aphasia therapy after stroke,
there is limited evidence for the comparative effectiveness of different aphasia interventions. Two commonly used
interventions, Constraint-induced Aphasia Therapy Plus (CIAT Plus) and Multi-modality Aphasia Therapy (M-MAT), are
hypothesised to rely on diverse underlying neural mechanisms for recovery and may be differentially responsive to
aphasia severity. COMPARE is a prospective randomised open-blinded end-point trial designed to determine
whether, in people with chronic post-stroke aphasia living in the community, CIAT Plus and M-MAT provide greater
therapeutic benefit compared to usual care, are differentially effective according to aphasia severity, and are cost-
effective. This paper details the statistical analysis plan for the COMPARE trial developed prior to data analysis.
Methods: Participants (n = 216) are randomised to one of three arms, CIAT Plus, M-MAT or usual care, and undertake
therapy with a study trained speech pathologist in groups of three participants stratified by aphasia severity. Therapy
occurs for 3 h blocks per day for 10 days across 2 weeks. The primary clinical outcome is aphasia severity as measured
by the Western Aphasia Battery-Revised Aphasia Quotient (WAB-R-AQ) immediately post intervention. Secondary
outcomes include WAB-R-AQ at 12-week follow-up, and functional communication, discourse efficiency, multimodal
communication, and health-related quality of life immediately post intervention and at 12-week follow-up.
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Results: Linear mixed models (LMMs) will be used to analyse differences between M-MAT and UC, and CIAT-Plus and
UC on each outcome measure immediately and at 12 weeks post-intervention. The LMM for WAB-R-AQ will assess the
differences in efficacy between M-MAT and CIAT-Plus. All analyses will control for baseline aphasia severity (fixed effect)
and for the clustering effect of treatment groups (random effect).
Discussion: This trial will provide relative effectiveness data for two common interventions for people with
chronic post-stroke aphasia, and highlight possible differential effects based on aphasia severity. Together
with the health economic analysis data, the results will enable more informed personalised prescription for
aphasia therapy after stroke.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN 12615000618550. Registered on 15 June 2016
Keywords: Aphasia, Chronic, Stroke rehabilitation, Statistical analysis plan, Randomised controlled trial
Introduction
Aphasia is an acquired language disability, impacting
all aspects of communication underpinned by lan-
guage: speech, reading, writing, and speaking. Aphasia
is present in approximately one third of stroke survi-
vors [1], with significant negative impacts on mental
health [2] and quality of life [3]. The 2016 Cochrane
review of speech and language therapy for aphasia
after stroke analysed 57 aphasia therapy trials and
showed statistically significant treatment effects
immediately after intervention but not at follow-up
[4]. Although there is a broad range of approaches to
aphasia intervention there is extremely limited evidence
concerning their differential effects [4]. Two commonly
utilised therapies, Constraint-induced Aphasia Therapy
Plus (CIAT Plus) [5] and Multi-modality Aphasia Therapy
(M-MAT) [6] are both intensive, high-dose interventions
aimed at improving verbal communication. However, they
are hypothesised to rely on different underlying neural re-
covery mechanisms and importantly may be differentially
effective based on overall aphasia severity. Determining
the most effective intervention for sub-groups of patients
with aphasia may lead to improved patient outcomes and
reduced health care costs.
COMPARE is a prospective, assessor-blinded, rando-
mised clinical trial with a group- randomised design,
operating in community sites across Australia and
New Zealand. The primary aim of the COMPARE trial
is to determine whether two contrasting, intensive
treatments for chronic post-stroke aphasia, CIAT Plus
and M-MAT, are superior to non-standardised, limited
aphasia therapy in the community (usual care: UC).
The primary endpoint is improvement on the WAB-R-
AQ [7] at therapy completion. A range of other aims
are addressed through secondary hypotheses listed
below. Ethics and local governance approval were ob-
tained from all hospital and university sites supporting
recruitment. Version 5.2 of the protocol, dated 7 May
2019, is current and the study protocol has been
published [8].
Primary hypothesis
Compared to UC, both CIAT Plus and M-MAT will
result in reduced aphasia severity as measured by the
WAB-R-AQ immediately post intervention.
Secondary hypotheses
Compared to UC, CIAT Plus and M-MAT will result in:
1. Reduced aphasia severity on the WAB-R-AQ [7] at
12-week follow-up.
2. Significantly more efficient connected speech
(Content Information Units [CIUs] per minute [9])
immediately post intervention and at 12-week
follow-up.
3. Significantly better ratings of functional
communication (Communicative Effectiveness
Index [CETI] [10]) immediately post intervention
and at 12-week follow-up.
4. Significantly better multimodal communication
(Scenario Test [11]) immediately post intervention
and at 12-week follow-up.
5. Significantly better quality of life (Stroke and
Aphasia Quality of Life Scale-39 g [SAQOL-39 g]
[12]) immediately post intervention and at 12-week
follow-up;
and we will also determine whether:
6. M-MAT will be more effective in reducing aphasia
severity (WAB-R-AQ [7]) immediately post
intervention and at the 12-week follow-up than
CIAT Plus for mild and severe aphasia, whereas
CIAT Plus will be more effective than M-MAT for
moderate aphasia, and
7. The interventions when compared to UC are cost-
effective.
The trial protocol includes additional hypotheses
related to a number of tertiary outcomes including an
optional sub-study. The economic evaluation for the
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main trial and the analysis of the tertiary outcomes will
be published separately. This paper provides a detailed
description of the COMPARE statistical analysis plan
(SAP Version 1.1 dated September 18, 2020) and has
been prepared in accordance with the published guide-
lines on the context of statistical analysis plans [13].
Summary of the study protocol
Written, informed consent is obtained from each partici-
pant and their carer/significant other using hospital- and
university-approved consent processes supported by apha-
sia friendly consent documents. Participants enrolled in
the trial are allocated to treatment groups of three partici-
pants, based on their aphasia severity (as determined by
the Western Aphasia Battery-Revised-Aphasia Quotient
[WAB-R-AQ] [2]) and geographic location.
Patient population
Participants include adults (18 years of age or older) liv-
ing in the community who were diagnosed with any type
of aphasia (WAB-R-AQ < 93.8) following a stroke at
least 6 months prior to enrolment in the trial. Partici-
pants are recruited through 22 hospitals with ethical
approval for the study and direct community advertising
in Australia and New Zealand. Inclusion criteria and
exclusion criteria are listed in the main protocol [8].
Randomisation
Eligible participants are randomised to one of three
arms: CIAT Plus, M-MAT, or UC. The intervention
protocol requires therapy to be provided face-to-face, in
groups of three participants. The members of a treat-
ment group therefore need to be in the same geographic
location. The trial uses a stratified group-randomisation
strategy. Once enrolled in the trial, participants are allo-
cated to treatment groups based on their aphasia sever-
ity (WAB-R-AQ mild = 93.7–62.6; moderate = 62.5–31.3;
severe < 31.3). The groups are then randomised to one
of three arms (M-MAT, CIAT Plus or UC) in a 1:1:1
ratio via a central allocation system using blocked
randomisation within each stratum.
Intervention
Participants randomised to the CIAT Plus and M-MAT
arms of the trial attend treatment sessions 3 h a day, five
times a week for 2 weeks (30 h of treatment in total). In
addition, a daily home practice communication task (15
min) is given to each participant and checked for
completion and logged the following day. CIAT Plus and
M-MAT are provided in community settings by a quali-
fied and study-trained speech pathologists. The UC arm
is the control arm of the trial. Participants randomised
to the UC arm undergo aphasia therapy in the commu-
nity at the type and frequency that is available to them
at the time of their recruitment and randomisation. For
some participants, UC may comprise no direct interven-
tion, while for others it may take the form of non-intense,
individual, computerised or social/support group sessions
(expected to be < 2 h per week). Full details of the inter-
vention are provided in the COMPARE Trial protocol [8].
Baseline and follow-up assessments
Pre-screening, screening and baseline evaluation proce-
dures are described in the main trial protocol [8]. The
assessed outcomes that are required for this statistical
analysis include baseline, post-intervention and 12-week
follow-up assessments and are detailed in the statistical
plan below. Participants are assessed for their medical
and stroke history. Baseline data collection includes the
documentation of: demographic details including age,
sex, past medical history, languages spoken, education
level, handedness [14], employment, Aboriginal or
Torres Strait islander status, and living arrangements;
stroke type and hemisphere, first or recurrent stroke,
stroke severity (mRS) [15]; apraxia of speech (Apraxia of
Speech Rating Scale) [16], self-rated fatigue and distress
(10-point scale), attention (Test of Everyday Attention
[17]: elevator counting and visual elevator subtests),
auditory verbal immediate and working memory (visual
memory spans [18]), nonverbal reasoning (Raven’s
coloured matrices [19]), semantic processing (Pyramids
and Palm Trees [20]), and the drawing, praxis and visual
orientation tasks of the Western Aphasia Battery Part 2 [7].
Sample size considerations
The study is powered to detect a difference of 5 points
on the WAB-R-AQ [7] at therapy completion. Although
the minimal clinically important difference for the
WAB-R-AQ [7] has not been formally determined, the
standard error of measurement for participants with
chronic aphasia is 4.33 points [21] with a 5-point differ-
ence considered clinically meaningful [22]. We used this
information to estimate the required sample size in two
steps. First, we conducted a naïve power analysis (which
did not account for the clustering effect of conducting
therapy in groups) which indicated a sample size of 198
to achieve 80% power at the 5% significance level. In the
second step, we adjusted for the clustering effect of
group therapy since the outcomes of participants from
within the treatment cluster may be correlated. We
anticipated a relatively small intraclass correlation coeffi-
cient (ICC) of 0.04. This is consistent with estimates of
ICC used in other studies, where prior information on
the size of the intraclass correlation was not available.
Based on this intraclass correlation coefficient and a
group size of 3, we calculated a maximum design effect
of 1.08. To adjust for the clustering effect, we multiplied
this value by the design effect, and rounded off to a
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multiple of 3, to obtain balanced allocation across the
three treatment groups. This yielded the required sample
size of 216.
Other data collection
Other data collected, including tertiary outcomes, re-
source use (for the economic evaluation) and therapy
characteristics are described in the main trial protocol
[8]. Collection of data related to therapy characteristics
and adverse events is summarised below.
During the trial intervention period, a daily log is com-
pleted for each trial participant which includes content,
duration and frequency of sessions, nature of home tasks
prescribed and completed, and participant self-rated
fatigue and distress. All trial data is logged in individual
electronic case report forms in a customised REDcap
database. Deviation from the prescribed therapy protocol
(CIAT Plus and M-MAT) is documented. Reasons for
withdrawal from the trial such as health-related compli-
cations and death are recorded. A participant diary is
provided to capture information on usual care therapy.
Participants are questioned about general health to
determine if there have been any adverse or serious
adverse events during the trial period.
Blinding
COMPARE is a complex behavioural intervention in
which the treating therapists are aware of the treatment
that they are providing. Participants assigned to UC will
be aware that they are not receiving intense treatment.
Therefore, neither the participants nor the treating ther-
apists are considered to be blinded. However, all assess-
ments (baseline, immediate post intervention, follow-up)
are conducted by independent assessors who are blinded
to treatment allocation.
Unblinding
Only the Data and Safety Monitoring Committee (DSMC)
have access to progressive data. The DSMC Chair is Profes-
sor Julie Bernhardt, University of Melbourne, Victoria,
Australia. The DSMC review unblinded data in accordance
with the DSMC Charter (Version 1.0, 10 November 2016).
Statistical analysis plan
Analysis principles and general considerations
All outcomes and analyses are prospectively characterised
as primary or secondary. Differences in all endpoints be-
tween the three arms of the trial (CIAT Plus, M-MAT, UC)
will be tested independently at the two-tailed 5% signifi-
cance level. All estimates of treatment effects will be
presented with 95% confidence intervals. No formal adjust-
ments will be undertaken to constrain the Type I error
associated with planned secondary or exploratory analyses.
The information provided by analyses is designed to
supplement the evidence from the primary analyses; it will
provide a more complete characterisation of the treatment
effects.
Intention to treat, sensitivity and per-protocol analyses
The analyses for all outcome measures (aphasia severity,
communication efficiency, functional communication,
total communication, quality of life) will be conducted
on an intention the treat (ITT) basis, that is, all partici-
pants will be analysed as members of the group to which
they were randomised, irrespective of whether they re-
ceived the allocated treatment or not. The ITT strategy
for COMPARE is based on the following principles:
 All available outcome data are collected on all
randomised participants
 All participants are analysed in the groups to which
they are randomised.
 All available outcome data will be used in the
primary analyses. The primary analyses will be
reported without imputation of missing data. If the
amount of missing data exceeds 10% at the primary
endpoint (therapy completion), missing data will be
imputed under the assumption that data is missing
at random.
 A sensitivity analysis including all randomised
individuals will be conducted. The sensitivity
analysis will consider alternative assumptions about
data missing not at random (MNAR).
Given COVID-19 pandemic impacts on face to face
assessments from March 23, 2020, some trial assess-
ments may be undertaken via videoconferencing. Assess-
ments undertaken via videoconferencing are considered
to be reliable and are expected to be consistent with
face-to-face assessments [23]. These will therefore be in-
cluded in the ITT analysis. The assessments conducted
via videoconferencing will be assessed for consistency
with the face-to-face assessments by comparing each
online assessment to:
 The mean for participants with similar baseline
characteristics, who received face-to-face assess-
ments at the given timepoint.
 The mean change from previous timepoint for
participants with similar baseline characteristics,
who received face-to-face assessments at the given
timepoint.
 A sensitivity analysis will be performed if the
assessments conducted via videoconferencing (or
change from previous timepoints) are found to be
more than 3 standard deviations from the
relevant mean face-to-face assessment (or relevant
mean change).
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A per-protocol analysis may be conducted separately
but will not be included in the primary results publica-
tion for this trial. The per-protocol analysis will be
described in a separate publication and will be based on
the following principles:
 The per-protocol cohorts will be based on whether
or not participants received the planned minimum
27 h/27 sessions of aphasia therapy completed in the
CIAT Plus/M-MAT therapy groups.
 Participants from the CIAT Plus/M-MAT groups
who do not achieve the minimum therapy amount
specified in the protocol will be treated as not
compliant with the treatment protocol and will be
included in the control group.
 All participants who are randomised to the UC
group will be included in the control group.
For primary and secondary analyses, the treatment
effects for the primary effectiveness outcomes will be
adjusted for baseline aphasia severity, measured by the
WAB-R-AQ [7] and baseline stroke severity measured
by the mRS [15]. Unadjusted analyses will be reported
separately from these pre-specified analyses.
Subgroup analyses will be carried out irrespective of
whether there is a significant treatment effect on the pri-
mary outcome. Their purpose is to supplement evidence
from the primary analyses to help to fully characterise
the treatment effect. Results from subgroup analyses will
be interpreted in this context.
All analyses will be conducted using the R Statistical
Programming Language [24].
Interim analysis and stopping rules
There are no formal interim analyses planned for this
trial. The DSMC periodically reviews data for the
primary outcome measure and safety, and advises the
chair of the management committee if, in their view, the
randomised comparisons have provided both (i) ‘proof
beyond reasonable doubt’ that one of the active arm in-
terventions (CIAT Plus or M-MAT) is clearly superior
or clearly inferior to usual care or because of safety
concerns and (ii) evidence that might influence future
patient management. The DSMC are guided by Haybittle-
Peto boundaries in making this determination. That is, they
work on the principle that a difference of at least 3 standard
errors in the analysis of effectiveness or serious adverse
events may be needed to justify halting or modifying the
study before the planned recruitment is completed.
Trial profile
The trial will be reported in accordance with the CON-
SORT statement for non-pharmaceutical trials and the
COMPARE therapeutic protocol conforms to the SPIR
IT statement. The report will include the number of
screened patients who met the inclusion criteria, the
number included, and the major reasons for exclusion of
eligible patients. At follow-up, the number of patients
withdrawn, lost to follow-up and the number who died
within that period will be reported (see Fig. 1.).
Patient characteristic and baseline comparisons
Baseline participant and stroke characteristics will be
presented for each of the three groups: CIAT Plus, M-
MAT and UC (Table 1). These will include age, gender,
geographic region (Australia/NZ), living arrangements,
stroke type, stroke severity (mRS) [15], and time since
stroke. Baseline aphasia severity (WAB-R-AQ) [7],
aphasia type (WAB-R-AQ) [7], apraxia of speech sever-
ity (ASRS) [16], naming (COMPARE naming battery)
[8], attention (TEA) [17], memory (Visual Span) [18],
non-verbal reasoning (Raven’s Coloured Matrices) [19],
drawing (WAB-R Part 2) [7], praxis (WAB-R Part 2)
[7], and communication efficiency (CIUs/minute) [9]
will be presented in Table 2.
Discrete variables will be summarised as frequencies
and percentages. Unless otherwise indicated in the
tables, percentages will be calculated according to the
number of participants for whom data are available. If
there are more than 5% missing values, the denominator
will be indicated in the corresponding summary table.
Continuous variables will be summarised by the mean
and standard deviation (SD) or by the median and inter-
quartile range (IQR). Durations and time intervals will
be summarised by medians and IQRs.
Primary outcome: reduction in aphasia severity
immediately post intervention
Primary outcome measure
The primary outcome is reduction in aphasia severity
immediately post intervention. Aphasia severity will be
measured by the WAB-R-AQ [7]. The WAB-R-AQ [7] is
a comprehensive measure incorporating production of
spoken language and auditory comprehension.
Statistical hypothesis
The primary research hypothesis is that compared to
UC, both CIAT Plus and M-MAT will result in reduced
aphasia severity on the WAB-R-AQ [7] immediately post
intervention. This will be tested by refuting the following
null hypotheses: (a) there is no difference in aphasia se-
verity, between the group receiving CIAT Plus and the
group receiving UC immediately post intervention, and
(b) there is no difference in aphasia severity, between the
group receiving M-MAT and the group receiving UC
immediately post intervention.
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Treatment of missing values
The primary analyses will be based on the intention to
treat principle, that is, all participants will be analysed in
the arm to which they were randomised. The primary
analysis will be reported without imputation of missing
data. If the amount of missing data warrants imputation
(i.e. the number of missing values exceeds 10%), missing
data imputation will be conducted under the assumption
that missing values are missing at random (MAR). That
is, it is assumed that the values of the missing data may
reasonably be predicted from all observed data. In
particular, it will be assumed that missing values of the
primary outcome measure (WAB-R-AQ at intervention
end) may be estimated from variables on which data has
been collected (e.g., baseline aphasia severity, baseline
stroke severity, age, gender, lesion size and location),
Fig. 1 CONSORT flow diagram
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and on the observed values of WAB-R-AQ. To ensure
robustness of the imputation, 20 imputed data sets will
be generated with a separate model being developed for
each imputation. These multiple imputations will be
conducted using chained equations. The pooled result of
these imputed models will be reported and compared
with the primary model (without imputed data). Based
on monitoring by the DSMC, 6% of the data for the
primary outcome measure in the COMPARE trial is
missing at the time of publication of the statistical
analysis plan. Sensitivity analyses that consider various
other plausible assumptions about missing data will be
presented.
Analysis method
The primary aim of this trial is to compare the effects of
CIAT Plus and M-MAT to usual care. This will be
achieved through the primary effectiveness hypothesis
which will be analysed using a linear mixed effects re-
gression model with WAB-R-AQ as the outcome meas-
ure. Each intervention group will be compared to the
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UC group on the primary outcome measure (WAB-AQ
immediately post intervention). The model will adjust
for differences in baseline aphasia severity and baseline
stroke severity by including the baseline WAB-R-AQ
and the baseline mRS as covariates in the model. The ef-
fect of conducting therapy in groups will be controlled
for by including the treatment group as a random effect.
The treatment effect will be reported as difference in
WAB-R-AQ with the corresponding 95% confidence
interval.
Secondary hypotheses
The following secondary hypotheses will be assessed:
1. Compared to UC, CIAT Plus and M-MAT will
result in a reduction in aphasia severity on the
WAB-R-AQ [7] at 12-week follow-up.
2. Compared to UC, CIAT Plus and M-MAT will
result in significantly more accurate and efficient
connected speech (CIUs [9] per minute) immediately
post intervention and at 12-week follow-up.
3. Compared to UC, CIAT Plus and M-MAT will
result in significantly better functional communication
(CETI [10]) immediately post intervention and at 12-
week follow-up.
4. Compared to UC, CIAT Plus and M-MAT will
result in significantly better multimodal communication
(Scenario Test [11]) immediately post intervention and
at 12-week follow-up.
5. Compared to UC, CIAT Plus and M-MAT will
result in a significantly better quality of life
(SAQOL-39 [12]) immediately post intervention
and at 12-week follow-up.
6. M-MAT will be more effective in reducing aphasia
severity (WAB-R-AQ [7]) immediately post
intervention and at the 12-week follow-up than
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CIAT Plus will be more effective than M-MAT for
moderate aphasia.
Secondary statistical hypotheses
The specified set of secondary effectiveness hypotheses in-
volve the assessment of the following statistical hypotheses:
1.1.CIAT Plus will result in greater reductions in
aphasia severity than UC, as measured by the
WAB-R-AQ [7], at 12 weeks post stroke.
1.2.M-MAT will result in greater reductions in aphasia
severity than UC, as measured by the WAB-R-AQ
[7], at 12 weeks post stroke.
2.1.CIAT Plus will result in better efficiency of
connected speech than UC, measured by CIUs/min
[9], immediately post intervention and at 12 weeks
follow-up.
2.2.M-MAT will result in better efficiency of connected
speech than UC, measured by CIUs/min [9],
immediately post intervention and at 12weeks follow-up.
3.1.CIAT Plus will result in better functional
communication than UC, measured by the CETI
[10], immediately post intervention and at 12 weeks
follow-up.
3.2.M-MAT will result in better functional
communication of connected speech than UC,
measured by the CETI [10], immediately post
intervention and at 12 weeks follow-up.
4.1.CIAT Plus will result in better multimodal
communication than UC, measured by the Scenario
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4.2.M-MAT will result in better multimodal
communication than UC, measured by the Scenario
Test [11], immediately post intervention and at 12
weeks follow-up.
5.1.CIAT Plus will result in better quality of life
than UC, measured by the SAQOL-39 [12], im-
mediately post intervention and at 12 weeks
follow-up.
5.2.M-MAT will result in better quality of life than UC,
measured by the SAQOL-39 [12], immediately post
intervention and at 12 weeks follow-up.
6.1.For participants with severe aphasia at baseline, M-
MAT will result in greater reduction in aphasia
severity than CIAT Plus, as measured by the WAB-
R-AQ [7], immediately post intervention and at 12
weeks follow-up.
6.2.For participants with moderate aphasia at baseline,
CIAT Plus will result in greater reduction in
aphasia severity than M-MAT, as measured by the
WAB-R-AQ [7], immediately post intervention and
at 12 weeks follow-up.
6.3.For participants with mild aphasia at baseline, M-
MAT will result in greater reduction in aphasia
severity than CIAT Plus, as measured by the
WAB-R-AQ [7], immediately post intervention
and at 12 weeks follow-up.
Analysis methods
Comparison of CIAT Plus and M-MAT with UC
immediately post intervention and 12weeks: Aphasia
Severity (WAB-AQ), Efficiency of Connected Speech
(CIUs/min), Functional Communication (CETI),
Multimodal Communication (Scenario Test), and
Quality of Life (SAQOL-39 g).
Longitudinal linear mixed models will be used to
compare each of the CIAT Plus and M-MAT groups to
the UC group on WAB-R-AQ, CIUs/min, CETI, Scenario
Test and SAQOL-39 g at therapy completion and 12
weeks. The between-group differences will be assessed
through a group × time interaction effects. The models
will adjust for baseline aphasia severity by including the
WAB-R-AQ at baseline as a covariate. Baseline stroke se-
verity will be controlled for by including mRS at baseline
as a fixed factor in the models. The treatment group will
be included as a random effect.
Comparison between CIAT Plus and M-MAT groups WAB-
R-AQ
A longitudinal linear mixed model will be used to assess
the difference between the CIAT Plus and M-MAT
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Fig. 3 Forest plot of the treatment effect on the primary outcome for M-MAT and UC at therapy completion
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at 12 weeks follow-up. The interaction effect: group ×
baseline severity will be included in the model to assess
the effects of CIAT Plus and M-MAT on participants
with different baseline severity classifications. The
between-group difference at each time point will be
assessed through the group× time interaction effect. The
model will adjust for baseline aphasia severity by includ-
ing the WAB-AQ at baseline as a covariate. Baseline
stroke severity will be controlled for by including mRS
at baseline as a fixed factor in the model. The treatment
group will be included as a random effect.
Handling of missing data
Missing data for secondary analyses will be handled as
described in the section on treatment of missing values.
Other secondary outcomes: safety important medical events
(IME) adverse events (AE) and serious adverse events (SAE)
Important medical events (IMEs), adverse events (AEs)
and serious adverse events (SAEs) are defined in the
main trial protocol. These are expected to be rare occur-
rences. Since the trial participants are medically stable
and living in the community, aphasia therapy is not
expected to have an effect on these events. Therefore, no
formal hypotheses have been stated about these out-
comes. All IMEs, AEs and SAEs will be reported by the
therapy group. As rare events, counts of IMEs, AEs and
SAEs are expected to have a Poisson or negative
binomial distribution. If the data suggests that there is a
between-group difference of greater than 3 standard de-
viations in any of these event types, then the distribu-
tions of these events will be modelled, and appropriate
generalised linear mixed models will be developed to as-
sess differences between groups.
Sensitivity analyses
Sensitivity analysis for the primary outcome will be con-
ducted under various assumptions about the missing data.
The main analysis is planned under an assumption of
missing at random; therefore, the sensitivity of the results
to plausible departures from MAR will be explored as a
part of an intention-to-treat analysis strategy [25–27]. The
2010 National Research Council Panel on the Handling of
Missing Data in Clinical Trials [27]. recommends a trans-
parent and easily interpretable method for conducting a
sensitivity analysis. Specifically, it recommends adding a
parameter (delta) to the mean response. The parameter,
delta, measures the degree of departure from missing at
random. We propose using this approach to conduct a
sensitivity analysis that assesses sensitivity of the results to
plausible departures from the MAR assumption in the
COMPARE trial. If the inference about the treatment ef-
fects can be overturned by plausible values of the delta
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Fig. 4 Forest plot of the treatment effect on the primary outcome for CIAT Plus and UC at therapy completion
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Tables and figures for the Main paper
Table 1 will report the main baseline demographic,
stroke characteristics. Table 2 will report baseline
speech, language, and cognition measures by participant
group. Table 3 will report key summary data about the
therapy characteristics (e.g. amount of therapy, number
of intervention levels passed, linguistic level reached)
provided for each group. Tables 4 and 5 will report the
primary and main secondary outcomes at immediate
post intervention and 12 weeks follow-up and Table 6
will report deaths and Serious Adverse Events. Figure 1
will be the CONSORT diagram. Figure 2 will present a
bar plot of the WAB-R-AQ at baseline, post intervention
and 12-week follow-up for the three arms. Figures 3 and 4
will be a forest plot of the treatment effect on the primary
outcome among different subgroups at therapy comple-
tion post stroke.
Summary
At the time of submission, 216 participants have been
recruited and randomised in the study. The final follow-
up data point was collected on July 23rd 2020, with data
lock anticipated in September 2020.
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